Sweet...a 60 Minutes appearance this Sunday!

Hopefully only a final retest of the recent lows, and not something more to it.

No chance, but fun to think that way.

Don't have issue with your points. Plenty of posts from any "group" are annoying. There's value from each too. DD posts tend to get lost while in this situation, but I don't think there are many new eyes in need of the DD at this moment.

I see what your saying with Aspire now.

I've been here throughout the afternoon and evening. Funny you believe that(ringleader), and didn't understand the basic mechanism of the Aspire funding.

I look at both sides of the equation, with a tilt and open mindedness towards the negative. We are, after all, in pennyland.

I have strong hopes for CTIX, and own a small position. I hope to up it to a huge position, but am looking for answers to a few questions first. Will they get up-listed, who is on the board, and what will the FDA grant for B?

Very tempted to up the position after closing the Aspire deal, and could see myself doing so early next week.

I think you are a little too sensitive and conspiratorial about those who are willing to see the possible downsides.

Thanks and wishing you, all the longs, and mostly the patients that could benefit from CTIX's pipeline, the best of success.

No, Aspire doesn't buy. They give money, and CTIX prints shares out of thin air for that money. Aspire then sells a portion or all of those shares, and hopes to get above what they "pay" for them.

Maybe Menon didn't have the money to pay, so shares was the only or best way. To think Aruda won't sell a portion would be naive.

It would work against Aspire too.

My fear of these possibilities were greatly reduced by the deal with Aspire.

NASDAQ is going to reject up-listing application. No independent board, or if there is one, doesn't give credibility. FDA is going to delay phase 3 trial for B, the trial won't start until Fall, and FDA will give least favorable designation. Followed by silence on the partnership front.

Not saying that any or all of that will happen, but that's the fear side of my analysis on CTIX. The sooner they are cleared up, the better.

Inline with previous deadline talk, so less than 90 days we should have an answer. I don't see why they won't choose to move forward when you consider the task orders that keep being placed and the credentialing WYY received from the government. Would be a huge win as they could then market to the commercial market.

Could get exciting around here soon and into the rest of the year.

Looking good! Should get a nice run, especially if the leaders in the sector keep showing robust revenue growth. I don't see why they won't.

Better way of framing it, for sure.

On the positive side, Aspire keeps believing there is an even bigger market for their shares each time. First $10 million, then 20, now 30 million. Don't discount that. They clearly believe in the business developments. CTIX has plenty of available cash to execute the business model through 2015 and probably some of 2016. This may well have helped them qualify for NASDAQ. Last, but not least, they can negotiate from strength for a partnership.

The downside is that while they can negotiate from strength, I think it means there is little partnership talks, or the current numbers being thrown at CTIX are very low offers.

Right after the conference in December 2014 I said the stock was likely dead money for 6 months, with a consolidation resembling the one at $1.70, but hopefully not as long of a consolidation. Not seeing reason to change that view 3 months later, but the old tri-fecta is the only thing I see left to change that view.

Looking possible.

Good analysis, as always. I don't believe the seller is done. Only taking a break hoping for strength, but yet to capitulate.

That's a tired belief you'll see on almost all message boards that don't wish to see reality. Reality is that a huge share transfer occurred and wishes to distribute some of them.

Next thing you'll probably say is that the big pharma companies are trying to bankrupt the company to get the IP for next to nothing.

Boheim is probably a net negative impact.

Impressive and credible BOD, will Nasdaq accept, and when and what designations will the FDA B are the only things that will rally and sustain the stock, in my opinion.

Credible third party endorsement as a wild card.

Watching level 2 will drive you mad. Next thing you'll know, you'll start telling people we never landed on the moon.

Give it another 24, and it could change. I think there remains some key events and information to occur and be known before the market knows what to really think about Leo.

The bill is in full view now for most. Aruda and his lawyers may be adding to the supply of shares too.

I don't believe in attempts. I have seen what you described before too. In that case, I think people just get jittery heading into important events. The results will ultimately drive the price.

I didn't like him commenting about the shorts, and think he should refrain from responding to this action as well. Not a precedent a CEO should make.

He's not looking the other way.

I think B-ABSSSI will be a success, but how it plays out before it is fully known is anyone's guess. Could be a hiccup with up-listing and/or not receive the designations hoped for into P3, and a longer wait for partnerships.

Did his position change because of a positive business development or to try and hold the stock together during a long delay and leverage negotiating ability? Hoping for the former, but it is a question I ask myself.

It's not a contradiction, but maybe lost in translation made it look that way?

I don't mean suddenly showing up on the new exchange. I mean in the announcement that they have been approved. I appreciate seeing an example of a company announcing up-listing with the announcement of filling the independent board.

I'm probably succumbing a little to fear on this issue after seeing that the NASDAQ requested more information. We obviously aren't privy to all the information. I think it will be tough for CTIX to get approved, unless they have a strong independent board. Maybe a partnership is waiting for the granting of P3. I believed that last December based on what Leo was saying. Maybe that partnership is all but done, and the board is being filled with one or more people recommended through the partnership. That would be pivotal in getting approval, I would think.

My perception is that the majority of the longs here believe that NASDAQ is a given, and that the tri-fecta is highly likely. I'm worrying that the delays on both fronts are lowering the likelihood. I've invested long enough to know that one should always be cognizant of these things. My basis is much higher than most here, so my risk is higher.

If CTIX is up-listed to NASDAQ in the next 60-90 days, and receives favorable designations into P3, I'll sing the praise, especially if a partnership is announced shortly after. Right now, I'm a little skeptical, forgive me. Leo hasn't fully earned my trust, and I think it is safe to say the market is trying to gauge this as well at current market cap.

I don't think it is fair to say that it is highly unlikely that there will be no NASDAQ up-list before Q4, and no partnership after being granted P3 that could still be many months out. Interesting to watch.

I hope that is correct, and think there is some clues from Leo's communications in September through December of 2014 to believe that.

I'm saying that the designations that the FDA might grant and a partnership are far more important than the up-list. An up-list without the other items would be a short lived rally. Big news without the up-list can still create a sustained rally, and inevitably would lead to a definitive up-list. Of course, would prefer an up-list, tri-fecta, and partnership progression.

Thank you for providing that example. Good to see.

Never seen that, and believe many have said the same.

Perhaps I'm being too pessimistic. Clarity would be great. Typically, it is better to simply execute an up list to the surprise of the shareholders. Will celebrate if I'm wrong.

I'm afraid they may view CTIX as too speculative when considering all the factors. It was quite the discussion on how CTIX could qualify, and when you add the strangeness of not revealing the board of directors with the stop-start intentions, I'm afraid they may get rejected. I'd put it at 50/50 after the last PR update.

I find it very hard to believe at (2) and/or (3) are done, and just waiting up-list. Can anyone make a convincing argument? It would seem to me that those would be material events that happen independently and have to be reported within specific time frames.

My belief is that they are working through, possibly on the brink of rejection to NASDAQ, and putting together data for the next FDA meeting to get through to phase 3. If there is a partnership in the wings, it's hinging on the results of that meeting. NASDAQ is great and all, but mostly meaningless compared to the other stuff.

If I'm a betting man, I think they'll get rejected from Nasdaq, granted P3 for B with less designations than our desires, and not have any news of a partnership. I am hoping for much better. I also hope that Dana-Farber publishes information about K that rocks our world.

I wish it wouldn't go down. I'd prefer clarity, but the waters are a little muddy. I think there is a decent risk that CTIX is rejected by NASDAQ, and that moving to P3 has further delays. There's reason to think that as the way the events have unfolded. The lack of institutional support or any third party verification at this stage is puzzling, and possibly troubling.

I don't know what will happen, and I hope that my previous post was clear in that intent. I think there is a risk of a bit of a breakdown here into the 2's, but CTIX has a remarkable ability to show it's just a little panic by small holders that will regret the very short term panic.

I predicted just after the CC in December that we would see a repeat of the long term consolidation around $1.70, but at a higher level and for a shorter time of around 6 months. Didn't know what the new $1.70 would be. I hope that prediction was true, and not something worse.

I would have preferred more clarity on the questions in my first paragraph, and to have held 3.40 or better, but here we are.

Leo has the people who have a basis under $2 holding tight. That's nice, but it people might be discounting that all their profit can disappear in an instance. In general, if your basis is higher and you haven't been here for over 2 years, I think Leo has created some uneasiness.

It is what it is. I watch with great anticipation. Will I reload lower? Maybe. Will I be able to hold whatever and wherever I buy more? Maybe. Ideally at a minimum, I would have much preferred holding 3.40 and keeping my full position. I do have a position, and would prefer to have a larger one that I didn't have to constantly de-risk. I'd feel better loading a break on the upside than a dip to the downside.

See you all next week.

CTIX has done really well at not breaking down in the past when it looks like it might. Will it fare as well as past threats?

Good stab there noretreat. Nice to see you here. Widepoint talked about revealing the big phone manufacturer when the company is ready in their marketing plan to do so. Starting to see the Samsung S6 commercials, and wonder if Widepoint might be in there.

Nice to see them continue to secure orders with different departments of the government through their large task order.

I contacted Nokomis Capital to try and get some color around their recent large buys. Have to think they know something.

Good luck.

I think expectations were for break-even earnings or better, and maybe more color on upcoming events.

Game of patience, that I think will be rewarded. Just need some sizzle to come through.

Very true. I have a small base position, but fluctuate on the size of the trading position. After the Monday release, I reduced my trading position to 0. I'm guessing some other traders did the same.

I just hope Leo doesn't screw up the up-list. The way it has been yes, no, yes, not announcing BOD, etc., I think there is a good risk that CTIX doesn't get accepted. Will feel so much better if they get accepted and we can view who wanted to join the board.

No near term catalyst, but very nice revenue growth. I see it staying within the current range $1.40-1.60, awaiting a catalyst from new OEM announcement, DHS, or Coastguard to send it to Riley's price target of $2.60. If done in favorable market conditions and sector attention, could easily shoot way past that target around summer.

Your thoughts?

CTIX up-listing has been a bit of saga. I hope it doesn't continue to be with a rejection. The board members thing is very strange, and maybe a protection of not building one if they don't end up getting up-listed.

Could be!